CORRELATION OF mRNA ALPHA RECEPTOR ESTROGEN (ER⍺) AND BETA RECEPTOR ESTROGEN (ERβ) EXPRESSION IN ADENOMYOSIS
DOI:
https://doi.org/10.61841/vvryhx20Keywords:
Adenomyosis, ERα mRNA expression, Erβ mRNA expressionAbstract
Adenomyosis is a condition in which endometrial tissue in the myometrium is hypertrophy and reactive. Adenomyosis is one of the gynecological problems that has an impact on a woman’s social life because of very painful symptoms during menstruation and infertility. The exact pathogenesis of adenomyosis is still unclear. The estrogen is thought to be involved in adenomyosis. Estrogen works on two estrogen receptors, ER⍺ and ERβ. Estrogen receptors are thought to be an important step in the occurrence of adenomyosis. The exact mechanism regarding the role of ERα and Erβ is still being investigated. Research that analyzes the comparison of ERα and Erβ mRNA expression on the incidence of adenomyosis has never been done in Indonesia. This study aims to analyze the correlation of mRNA ERα and ERβ expression in adenomyosis. Research was done at an educational hospital in Makassar from January to August 2019. an observational study with a cross-sectional study approach, a sample of 15 people diagnosed with adenomyosis and 15 people diagnosed not with adenomyosis. Tissues were examined in the Pathology Anatomy Laboratory and Erα/Erβ mRNA expressions in the Molecular Biology and Immunology Laboratory using the real-time PCR method. The result of this study is that ERα and ERβ mRNA expression increased in the adenomyosis group compared to the non-adenomyosis group. Pearson correlation showing strong positive correlation between ERα mRNA and ERβ mRNA expression with p-value of <0.0001 and correlation coefficient (r) of 0.692. In adenomyosis, the expression of ERβ is higher than Erα, with an average Erβ mRNA expression value of 9.85 ± 1.44 and mRNA Erα expression of 8.09 ± 1.21. so there is a significant relationship between mRNA ERα and Erβ expression on the incidence of adenomyosis, especially more on Erβ
Downloads
References
1. Abdullah, N. 2008. Analisis polimorfisme gen vascular endothelial growth factor (VEGF) pada endometriosis.
Program Pascasarjana, Disertasi, Universitas Hasanuddin, Makassar.
2. Adamson, G. D. & Pasta, D. J. 2010. Endometriosis fertility index : the new, validated endometriosis staging
system. Fertility and Sterility, 94, 1609-15.
3. Baziad, A. 2008. Endometriosis pada Endokrinologi Ginekologi, Jakarta, Media Aesculapius Fakultas Kedokteran University Indonesia.
4. Bedaiwy & Falcone, T. 2004. Laboratory testing for endometriosis. Clin Chim Acta, 340, 41-56.
5. Bernadete, A. & Marqui, T. D. 2012. Genetic polymorphisms and endometriosis: contribution of genes that
regulate vascular function and tissue remodeling. Revista da Associação Médica Brasileira, 58, 620-32.
6. Bozzuto, G., Ruggieri, P. & Molinari, Molecular aspects of tumor cell migration and invasion. Ann Ist Super
Sanita, 46, 66-80.2010
7. Campbell, I. & Thomas, E. Endometriosis: Candidate genes. Human Reproduction Update, 7, 15-20. 2011
8. Clayton SG, Lewis TLT, Pinker G. Gynaecology by Ten Teachers, 13th ed., London: Butler & Tanner Ltd.
1981;43-47
9. Cunningham FG, Mac Donald PC, Gant NF. Williams obstetri. Edisi ke-18. Jakarta: EGC, 1995; 1097-1099
10. D'Hooge, T., Vodolazkaia, A., Kyama, C., Mwenda, J. M., & Simoens, S. Health economics of endometriosis. In: Rombauts, L., Tsaltas, J., Maher, P., & Healy, D. (eds.) Endometriosis 2008. 1 ed. Melbourne: Blackwell Publishing. 2008
11. Daryl K, Granner MD. Harper’s Biochemistry, 22nd ed., London: Appleton & Lange, 1990; 521-523
12. Djuwantono Tono, Bayuaji Hartanto. Step by Step Penanganan Kelainan Endokrinologi Reproduksi dan
Fertilitas dalam praktik sehari-hari. Departemen Obstetri dan Ginekologi Fakultas Kedokteran University
Pajajaran. Bandung p263-68. Sagung Seto. 2012
13. Elliot, J. E., Abduljabar, H., & Morris, M. 2011. Presurgical management of dysmenorrhea and endometriosis
in a patient with Mayer-Rokitansky-Kustner-Hauser syndrome. Fertility and Sterility, 96, 86-89.
14. Felmeden, D., Blann, A., & Lip, G. Angiogenesis: basic pathophysiology and implications for disease.
European Heart Journal, 24, 586-603.2010
15. Fitrina M., et al., Karakteristik Pasien Adenomiosis dengan Gambaran Ultrasonografi di Rumah Sakit Dr.
Hasan Sadikin Bandung Periode 2015-2016. Obgynia, 2018; 1(1): 35-39
16. Fritz MA dan Speroff L. 2011. Hormon Biosynthesis, Metabolism, and Mechanism of Action In Clinical
Gynecologic Endocrinology and Infertility. Philadelphia: Lippincott Williams & WIlkins 65-66
17. Hadisaputra, W. Kombinasi Petanda Biologis (IL-6, TNF-α, MMP-2, VEGF) dan gejala serta tanda klinis
Sebagai model prediktor diagnosis endometriosis perempuan masa reproduksi. Program Pascasarjana,
Disertasi, Universitas Indonesia, Jakarta. 2012
18. Irfan, Rambulangi, J., & Bandaso, R. Tinjauan kasus Endometriosis di bagian patologi anatomi fakutas
kedokteran Unhas. Fakultas Kedokteran Universitas Hasanuddin.2010
19. GeneCards. 2014. Matrix Metallopeptidase 2 (Gelatinase A, 72k) Da Gelatinase,... [Online]. Israel: Crown
Human Genome Center, Department of Molecular Genetics, the Weizmann Institute of Science
20. Gruber CJ, Tschugguei W, Schneebeger C, Huber JC. Production and action of estrogens. N Engl J Med 2002;
346: 340-50
21. Hapangama DK, Kamal AM, and Bulmer JN. Estrogen Receptor: the Guardian of the Endometrium. Human
Reproductive Update, 2015; 21(2): 174-193
22. Huang B., et al. Differential Expression of Estrogen Receptor α, β1, and β2 in Lobular and Ductal Breast
Cancer. PNAS, 2014; 111(5): 1933-1938
23. Hull, M., Charnock-Jones, D., Chan, C., Bruner-Tran, K., Osteen, K., Tom, B., Fan, T. & Smith, S. 2003.
Antiangiogenic agents are effective inhibitors of endometriosis. J Clin Endocrinol Metab, 88, 2889-99.
24. Jacoeb, T. Z. & Hadisaputra, W. 2009. Penanganan endometriosis: Panduan klinis dan algorithm, Jakarta, CV.
Sagung Seto.
25. Jones HW, Jones GS. 1981, Novaks textbook of gynecology, 10th ed., Baltimore: The Williams & Wilkins
Company,; 29-39
26. Kyama, C. M., Debrock, S., Mwenda, J. M., & D'Hooghe, T. M. 2003. Potential involvement of the immune
system in the development of endometriosis. Reproductive Biology and Endocrinology, 1.
27. Li JJ, et al. Expression Pattern of G-Protein-Coupled Estrogen Receptor in Myometrium of Uteri with and
without Adenomiosis. Biomed Research International, 2017: 1-7
28. Lebovic, D.I., Mueller, M. D., Hornung, D., & Taylor, R. N. 2002. Immunology of endometriosis. Immunology
Allergy Clinics of North America, 22(3), 1-12.
29. Manuaba, I. B. G. F. 2012. Kontribusi endoglin pada endometriosis: analisis terhadap kadar endoglin dan polimorfisme gen endoglin. Program Pasca sarjana Disertasi, Universitas Hasanuddin, Makassar.
30. Mehasseb MK., et al. Estrogen and Progesterone Receptor Isoform Distribution through the Menstrual Cyclr in Utei with and without Adenomyosis. American Society for Reproductive Medicine, 2011; 95(7): 2228-2235
31. Meresman, G. F., Vighi, S., Buquet, R. A., Ortiz, O. C., Tezone, M., & Rumi, L. S. 2000. Apoptosis and
expression of Bcl-2 and Bax in eutopic endometrium from women with endometriosis. Fertility and Sterility,
74, 760-66.
32. Mizumoto, H. 2002. Expression of matrix metalloproteinases in ovarian endometriomas:
immunohistochemical study and enzyme immunoassay. Life Science, 71, 259–73.
33. Nap, A. W., Groothuis, P. G., Demir, A. Y., Evers, J. L. H., & Dulselman, G. A. J. 2004. Phatogenesis of
endometriosis. Best Practice & Research Clinical Obstetrics and Gynecology, 18:2, 233-244.
34. O’Malley B, Straat CA. Yen Jaffe. 1991, Reproductive Endocrinology, 3rd ed., Philadelphia: WB Saunders
Company, 156-168
35. Olive, D. L., Lindheim, S. R., & Pritts, E. A. 2004. New medical treatments for endometriosis. Best Practice &
Research Clinical Obstetrics and Gynecology, 18, 319-28.
36. Overton, C., Davis, C., McMillan, L., & Shaw, R. W. 2007. An Atlas Endometriosis, United Kingdom, Informa
Heathcare.
37. Paterni I., et al. Estrogen Receptor Alpha (ER-α) and Beta (ER-β), Subtype-Selective Ligands and Clinical
Potential. Steroid, 2014; 0: 13-29
38. Seli, E., Berkkanoglu, M., & Arici, A. 2003. Pathogenesis of endometriosis. Obstetrics and Gynecology Clinics,
30.
39. Simmen R. dan Kelley AS. Reversal of Fortune: Estorgen Receptor Beta in Endometriosis. Journal of
Molecular Endocrionology, 2016;57:F23-27
40. Speroff, L. & Fritz, A. 2011. Endometriosis. Clinical Gynecologic Endocrinology and Fertility. Eight ed.
Philadelphia: Lippincott Williams and Wilkins
41. Suherman KS. 1995. Farmakologi dan terapi. Edisi ke-4 Jakarta: Bagian Farmakologi FK-UI, 439-443
42. Supono. 1985. Ilmu kebidanan. Bagian kebidanan dan kandungan FK-Unsri. Palembang;28-29
43. Suresh, P. S., Venkatesh, T., Rajan, T., & Tsutsumi, R. 2013. Molecular Pathology and Therapy of
Endometriosis: Revisited. Andrology & Gynecology: Current Research, 1.
44. Valladares F., et al. Characteristics of Estrogen Receptors Alpha and Beta in Uterine Leiomyoma Cells. American Society for Reproductive Medicine, 2006; 86: 1736-43
45. Vannuccini S., et al. Pathogenesis of Adenomyosis: and Update on Molecular Mechanism. Reproductive Biomedicine Online, 2017; 35: 592-601
46. Wibowo B. Ilmu kandungan. 1994, Edisi ke-2. Jakarta: Yayasan Bina Pustaka Sarwono Prawiroharjo; 70-74
47. Zhang, S., Li, L., Lin, J.-Y., & Lin, H. 2003. Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma. World Journal of Gastroenterology, 9, 899-904.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 AUTHOR
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
